Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K N Price

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialL Mauriac, A Keshaviah, M Debled, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2011
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trialG Viale, M M Regan, P Dell'Orto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2009
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancerG Viale, A Giobbie-Hurder, B A Gusterson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2000
Identifying breast cancer patients at high risk for bone metastasesM Colleoni, A O'Neill, A Goldhirsch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2004
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experienceG Berclaz, S Li, K N Price, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2000
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VIID Crivellari, M Bonetti, M Castiglione-Gertsch, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2007
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialL Mauriac, A Keshaviah, M Debled, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2011
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trialG Viale, M M Regan, P Dell'Orto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 28, 2009
Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancerG Viale, A Giobbie-Hurder, B A Gusterson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2000
Identifying breast cancer patients at high risk for bone metastasesM Colleoni, A O'Neill, A Goldhirsch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 21, 2004
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experienceG Berclaz, S Li, K N Price, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2000
Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VIID Crivellari, M Bonetti, M Castiglione-Gertsch, et al.
Pageof 4